NCT00954915View on ClinicalTrials.gov

Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Psoriasis
Interventions
BIOLOGICAL

teplizumab

Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.

Trial Locations (2)

48109

University of Michigan Medical Center, Ann Arbor

97239

Oregon Health & Science University, Portland

Sponsors

Lead Sponsor

MacroGenics
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

MacroGenics

INDUSTRY

NCT00954915 - Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis | Biotech Hunter | Biotech Hunter